What Makes 10x Genomics (TXG) a Strong Position Ahead of Its H2 2026 Atera Launch?
10x Genomics' Xenium Platform To Be Deployed By Fudan University Shanghai Cancer Center, Shanghai Precision Diagnostics In 24-Month Trial
TXG Q3 2026 deep dive: spatial platform launch and AI-driven demand shape outlook
JP Morgan Maintains Neutral on 10x Genomics, Lowers Price Target to $65
Barclays Maintains Overweight on 10x Genomics, Lowers Price Target to $70
10x Genomics (TXG) Could Be 24% Undervalued After Raising Its 2026 Revenue Outlook
UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $61
Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $60
10x Genomics Inc (TXG) (Q3 2026) Earnings Call Highlights: Atera Launch Takes Flight as Revenue ...
TXG Q3 Earnings Call Highlights Atera Launch and Raised Outlook
What 10x Genomics (TXG) Said on Its Q3 Earnings Call
10x Genomics, Inc. Q3 2026 Earnings Call Summary
Stifel Maintains Buy on 10x Genomics, Raises Price Target to $68
10x Genomics (TXG) Q3 2026 Earnings Call Transcript
10X Genomics (NASDAQ:TXG) Earnings: EPS Beat, Revenue In Line, Shares Fall 10.4%
Compared to Estimates, 10x Genomics (TXG) Q3 Earnings: A Look at Key Metrics
10x Genomics’s (NASDAQ:TXG) Q3 2026 sales top estimates but stock drops
10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates
10x Genomics: Q3 Earnings Snapshot
10x Genomics Reports Third Quarter 2026 Financial Results
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.